Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, ...

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...